Policy & Regulation

ICMR Issues a Historic Directive: Indian Medical Research Must Be Built on Indian Data — Not Western Assumptions

By BHC, Editor in Chief · April 6, 2026 · 5 min read

BHC, Editor in Chief — ICMR Issues a Historic Directive: Indian Medical Research Must Be Built on Indian Data — Not Western Assumptions

Summary

  • ICMR has issued a directive pushing for medical research built on Indian patient data. Here is why this matters and what it means for clinical practice, pharmaceutical development, and healthtech in India.

There is a fundamental problem at the heart of how medicine is practised in India — and it has been hiding in plain sight for decades. The vast majority of clinical research that informs drug dosing guidelines, disease screening thresholds, surgical protocols, and treatment algorithms was conducted on Western patient populations — predominantly white, predominantly male, predominantly living in high-income countries with very different dietary habits, environmental exposures, and genetic profiles from the 1.4 billion people in India.

"Western data on disease patterns, genetics, and drug responses cannot be directly applied to Indian patients. India's disease burden, genetics, diet, and environment are distinct. Our research must reflect that."

The Indian Council of Medical Research has now formally addressed this problem through a new directive that pushes for Indian-centric medical research — explicitly acknowledging that genetic, dietary, and environmental differences between Indian and Western populations mean that research findings from the West cannot simply be applied to Indian patients without validation. This is not a theoretical concern. It has real, measurable consequences for clinical care.

**The Problem in Concrete Terms

Consider body mass index. The BMI thresholds used globally to classify healthy, overweight, and obese individuals were derived from studies of European and American populations. South Asians develop cardiometabolic disease — diabetes, hypertension, cardiovascular disease — at significantly lower BMI values than these thresholds suggest. An Indian patient with a BMI of 23, classified as 'healthy' by Western standards, may carry significant visceral fat and metabolic risk that a clinician trained on Western guidelines would not flag for intervention.

Consider drug dosing. Pharmacogenomics — the study of how genetic variations affect drug metabolism — has shown that specific enzyme variants that affect how drugs are processed are distributed very differently across Asian and European populations. Dosing guidelines developed for European patients may result in sub-therapeutic dosing or toxicity in Indian patients with different metabolic enzyme profiles.

Consider disease onset patterns. Non-communicable diseases in India occur 10 to 15 years earlier than in Western populations. A screening programme designed to begin diabetes monitoring at age 45 — appropriate for the European population that informed its design — misses the window of preventive opportunity for an Indian population where insulin resistance may develop in the early 30s.

**What the ICMR Directive Actually Requires

The directive pushes for a systematic shift: medical research in India should be built on Indian patient data, validated for Indian populations, and reflect the specific genetic, dietary, and environmental context of Indian patients. This applies across the spectrum — from drug development and clinical trials to diagnostic screening thresholds, treatment protocols, and public health guidelines.

Practically, this means pharmaceutical companies seeking regulatory approval in India will face increasing pressure to include Indian patient cohorts in their clinical trial designs, not simply extrapolate from international data. It means diagnostic companies building AI tools for Indian clinical settings need to validate their models on Indian patient populations, not just report performance metrics from Western datasets. And it means hospitals and clinical guidelines bodies in India need to review their standard of care protocols against Indian evidence, not just import WHO or international society guidelines wholesale.

**The Opportunity for Indian Healthtech

The ICMR directive is not just a compliance signal — it is a market signal. India needs Indian clinical data infrastructure: platforms for clinical trial management, patient registries, genomic data collection, and real-world evidence generation that are built for Indian healthcare settings and validated for Indian populations. This is a category that Indian health-tech companies are uniquely positioned to build — not just for the Indian market, but as a globally differentiated offering for anyone who needs to understand how medicine works in one of the world's largest and most genetically diverse patient populations.

AI diagnostic companies like Qure.ai have already demonstrated that AI models trained on Indian clinical data can outperform globally trained models for Indian patients. This principle extends across oncology, cardiology, endocrinology, and beyond. The ICMR directive provides policy tailwind for the entire category.

**BHC Perspective

At Bengaluru Health Community, we believe the ICMR directive is one of the most important policy signals of 2026 for the Indian healthcare innovation ecosystem. It creates both an obligation and an opportunity: the obligation to build clinically rigorous products validated for Indian patients, and the opportunity to create research infrastructure and clinical data assets that are irreplaceable for anyone who wants to practise or develop medicine in India at scale. Founders building in clinical AI, diagnostics, and drug development should be building this Indian-data-first approach into their core product strategy.

**Frequently Asked Questions

Q: Why has ICMR issued an India-centric research directive?
A: ICMR issued the directive because Indian patients have distinct genetic profiles, dietary habits, and environmental exposures that mean Western clinical data, drug dosing guidelines, and disease screening thresholds may not apply directly. South Asians develop cardiometabolic disease at lower BMIs, have different pharmacogenomic profiles, and experience non-communicable disease onset 10-15 years earlier than Western populations.

Q: How does the ICMR directive affect pharmaceutical companies?
A: Pharma companies will face increasing pressure to include Indian patient cohorts in clinical trial designs rather than extrapolating from international data. Drug dosing guidelines, efficacy data, and safety profiles need to be validated specifically for Indian populations.

Q: What opportunity does this create for Indian healthtech companies?
A: The directive creates demand for Indian clinical data infrastructure — patient registries, clinical trial platforms, genomic data systems, and AI diagnostic tools trained and validated on Indian patient data. This is an area where Indian healthtech companies have a structural advantage.